Novartis digs deeper into cancer with up to $750 million Aduro deal

March 30, 2015 4:55 PM

11 0

(Reuters) - Swiss drugmaker Novartis (NOVN.VX) is digging deeper into cancer immunotherapy, one of the hottest areas of drug research, through a tie-up with Aduro Biotech (ADRO.O) worth up to $750 million.

The move comes as the privately owned California-based biotech group prepares for a $86 million initial public offering (IPO), details of which were announced earlier this month.

Also read: 113 Houston companies make Inc. 5000 list of fast growers

Read more

To category page